ESBATech AG - Taking yeast from the brewery to drug discovery

ESBATech AG is specialized in pre-clinical research which comprises the identification of disease-relevant target genes (functional genomics) and lead compounds (drug discovery). For identification and validation of target genes, ESBATech has developed three novel functional genomics technologies. These technologies are currently being applied to the field of Alzheimer's disease, breast cancer and ovarian cancer. For lead compound identification, ESBATech has developed two novel platform technologies which are applied to skin cancer. Furthermore, ESBATech has developed a unique antibody platform technology which can be applied to the areas of therapeutics, diagnostics, and functional genomics. All these platform technologies utilize the model organism yeast which enables the rapid and inexpensive reconstitution of in vivo molecular components of human diseases. High-throughput screenings to cure a disease at the molecular level or to identify novel target genes are routinely performed by analyzing more than 10 million candidates in parallel within two weeks.